FOLFOXIRI plus Bevacizumab Versus FOLFOX plus Panitumumab for Metastatic Left-Sided RAS/BRAF Wild-Type Colorectal Cancer: Which "Side" Are You On?

Yu, Irene S; Loree, Jonathan M

Yu, Irene S; Loree, Jonathan M.

Affiliation

Yu IS; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Loree JM; Department of Medical Oncology BC Cancer, Vancouver, British Columbia, Canada.

Oncologist ; 26(4): 277-280, 2021 04.

Article in En | MEDLINE | ID: mdl-33539032

Subject(s)

Colorectal Neoplasms; Proto-Oncogene Proteins B-raf; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Bevacizumab/therapeutic use; Camptothecin/analogs & derivatives; Camptothecin/therapeutic use; Colorectal Neoplasms/drug therapy; Fluorouracil/therapeutic use; Humans; Leucovorin/therapeutic use; Organoplatinum Compounds; Panitumumab/therapeutic use; Proto-Oncogene Proteins B-raf/genetics

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Colorectal Neoplasms / Proto-Oncogene Proteins B-raf Type of study: Clinical_trials Limits: Humans Language: En Journal: Oncologist Journal subject: NEOPLASIAS Year: 2021 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google